Table of Contents Author Guidelines Submit a Manuscript
International Journal of Hypertension
Volume 2015, Article ID 896861, 6 pages
http://dx.doi.org/10.1155/2015/896861
Review Article

The ACE2/Apelin Signaling, MicroRNAs, and Hypertension

1State Key Laboratory of Medical Genomics, Ruijin Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai 200025, China
2Shanghai Key Laboratory of Hypertension, Shanghai Institute of Hypertension, Shanghai 200025, China
3Institute of Health Sciences, Shanghai Institute for Biological Sciences, Chinese Academy of Sciences, Shanghai 200025, China
4Department of Cardiology, Guangdong General Hospital, Guangdong Academy of Medical Sciences, Guangzhou 510080, China

Received 17 December 2014; Accepted 23 February 2015

Academic Editor: Markus Schlaich

Copyright © 2015 Lai-Jiang Chen et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. J. Y. Moon, “Recent update of renin-angiotensin-aldosterone system in the pathogenesis of hypertension,” Electrolytes & Blood Pressure, vol. 11, no. 2, pp. 41–45, 2013. View at Publisher · View at Google Scholar
  2. V. B. Patel, J.-C. Zhong, D. Fan et al., “Angiotensin-converting enzyme 2 is a critical determinant of angiotensin II-induced loss of vascular smooth muscle cells and adverse vascular remodeling,” Hypertension, vol. 64, no. 1, pp. 157–164, 2014. View at Publisher · View at Google Scholar · View at Scopus
  3. Z. Zhang, L. Chen, J. Zhong, P. Gao, and G. Y. Oudit, “ACE2/Ang-(1–7) signaling and vascular remodeling,” Science China Life Sciences, vol. 57, no. 8, pp. 802–808, 2014. View at Publisher · View at Google Scholar
  4. X.-H. Yu, Z.-B. Tang, L.-J. Liu et al., “Apelin and its receptor APJ in cardiovascular diseases,” Clinica Chimica Acta, vol. 428, pp. 1–8, 2014. View at Publisher · View at Google Scholar · View at Scopus
  5. X. Song, D. Shan, J. Chen, and Q. Jing, “miRNAs and lncRNAs in vascular injury and remodeling,” Science China Life Sciences, vol. 57, no. 8, pp. 826–835, 2014. View at Publisher · View at Google Scholar
  6. E. Bronze-da-Rocha, “MicroRNAs expression profiles in cardiovascular diseases,” BioMed Research International, vol. 2014, Article ID 985408, 23 pages, 2014. View at Publisher · View at Google Scholar
  7. S. Bátkai and T. Thum, “MicroRNAs in hypertension: mechanisms and therapeutic targets,” Current Hypertension Reports, vol. 14, no. 1, pp. 79–87, 2012. View at Publisher · View at Google Scholar · View at Scopus
  8. M. Ha and V. N. Kim, “Regulation of microRNA biogenesis,” Nature Reviews Molecular Cell Biology, vol. 15, no. 8, pp. 509–524, 2014. View at Publisher · View at Google Scholar
  9. A. Saj and E. C. Lai, “Control of microRNA biogenesis and transcription by cell signaling pathways,” Current Opinion in Genetics and Development, vol. 21, no. 4, pp. 504–510, 2011. View at Publisher · View at Google Scholar · View at Scopus
  10. C. C. Xu, W. Q. Han, B. Xiao, N. N. Li, D. L. Zhu, and P. J. Gao, “Differential expression of microRNAs in the aorta of spontaneously hypertensive rats,” Sheng Li Xue Bao, vol. 60, no. 4, pp. 553–560, 2008. View at Google Scholar
  11. W.-H. Wu, C.-P. Hu, X.-P. Chen et al., “MicroRNA-130a mediates proliferation of vascular smooth muscle cells in hypertension,” American Journal of Hypertension, vol. 24, no. 10, pp. 1087–1093, 2011. View at Publisher · View at Google Scholar · View at Scopus
  12. J. E. Kontaraki, M. E. Marketou, E. A. Zacharis, F. I. Parthenakis, and P. E. Vardas, “Differential expression of vascular smooth muscle-modulating microRNAs in human peripheral blood mononuclear cells: novel targets in essential hypertension,” Journal of Human Hypertension, vol. 28, no. 8, pp. 510–516, 2014. View at Publisher · View at Google Scholar · View at Scopus
  13. J. E. Kontaraki, M. E. Marketou, E. A. Zacharis, F. I. Parthenakis, and P. E. Vardas, “MicroRNA-9 and microRNA-126 expression levels in patients with essential hypertension: potential markers of target-organ damage,” Journal of the American Society of Hypertension, vol. 8, no. 6, pp. 368–375, 2014. View at Publisher · View at Google Scholar · View at Scopus
  14. S. Li, J. Zhu, W. Zhang et al., “Signature microRNA expression profile of essential hypertension and its novel link to human cytomegalovirus infection,” Circulation, vol. 124, no. 2, pp. 175–184, 2011. View at Publisher · View at Google Scholar · View at Scopus
  15. E. Schulz, T. Gori, and T. Münzel, “Oxidative stress and endothelial dysfunction in hypertension,” Hypertension Research, vol. 34, no. 6, pp. 665–673, 2011. View at Publisher · View at Google Scholar · View at Scopus
  16. L. Elia, M. Quintavalle, J. Zhang et al., “The knockout of miR-143 and -145 alters smooth muscle cell maintenance and vascular homeostasis in mice: correlates with human disease,” Cell Death and Differentiation, vol. 16, no. 12, pp. 1590–1598, 2009. View at Publisher · View at Google Scholar · View at Scopus
  17. T. Boettger, N. Beetz, S. Kostin et al., “Acquisition of the contractile phenotype by murine arterial smooth muscle cells depends on the Mir143/145 gene cluster,” The Journal of Clinical Investigation, vol. 119, no. 9, pp. 2634–2647, 2009. View at Publisher · View at Google Scholar · View at Scopus
  18. M.-H. Kim, O. Ham, S.-Y. Lee et al., “MicroRNA-365 inhibits the proliferation of vascular smooth muscle cells by targeting cyclin D1,” Journal of Cellular Biochemistry, vol. 115, no. 10, pp. 1752–1761, 2014. View at Publisher · View at Google Scholar
  19. B. Song, Z.-Z. Zhang, J.-C. Zhong et al., “Loss of angiotensin-converting enzyme 2 exacerbates myocardial injury via activation of the CTGF-fractalkine signaling pathway,” Circulation Journal, vol. 77, no. 12, pp. 2997–3006, 2013. View at Publisher · View at Google Scholar · View at Scopus
  20. B. Hu, J. T. Song, H. Y. Qu et al., “Mechanical stretch suppresses microRNA-145 expression by activating extracellular signal-regulated kinase 1/2 and upregulating angiotensin- converting enzyme to alter vascular smooth muscle cell phenotype,” PLoS ONE, vol. 9, no. 5, Article ID e96338, 2014. View at Publisher · View at Google Scholar · View at Scopus
  21. K. Kohlstedt, C. Trouvain, T. Boettger, L. Shi, B. Fisslthaler, and I. Fleming, “AMP-activated protein kinase regulates endothelial cell angiotensin-converting enzyme expression via p53 and the post-transcriptional regulation of microRNA-143/145,” Circulation Research, vol. 112, no. 8, pp. 1150–1158, 2013. View at Publisher · View at Google Scholar · View at Scopus
  22. R. Goyal, D. Goyal, A. Leitzke, C. P. Gheorghe, and L. D. Longo, “Brain renin-angiotensin system: fetal epigenetic programming by maternal protein restriction during pregnancy,” Reproductive Sciences, vol. 17, no. 3, pp. 227–238, 2010. View at Publisher · View at Google Scholar · View at Scopus
  23. J. R. Kemp, H. Unal, R. Desnoyer, H. Yue, A. Bhatnagar, and S. S. Karnik, “Angiotensin II-regulated microRNA 483-3p directly targets multiple components of the rennin-angiotensin system,” Journal of Molecular and Cellular Cardiology, vol. 75, pp. 25–39, 2014. View at Publisher · View at Google Scholar
  24. X. Jiang, Q. Ning, and J. Wang, “Angiotensin II induced differentially expressed microRNAs in adult rat cardiac fibroblasts,” Journal of Physiological Sciences, vol. 63, no. 1, pp. 31–38, 2013. View at Publisher · View at Google Scholar · View at Scopus
  25. P. L. Jeppesen, G. L. Christensen, M. Schneider et al., “Angiotensin II type 1 receptor signalling regulates microRNA differentially in cardiac fibroblasts and myocytes,” British Journal of Pharmacology, vol. 164, no. 2, pp. 394–404, 2011. View at Publisher · View at Google Scholar · View at Scopus
  26. A. Sen, P. Most, and K. Peppel, “Induction of microRNA-138 by pro-inflammatory cytokines causes endothelial cell dysfunction,” FEBS Letters, vol. 588, no. 6, pp. 906–914, 2014. View at Publisher · View at Google Scholar
  27. T. V. Eskildsen, P. L. Jeppesen, M. Schneider et al., “Angiotensin II regulates microRNA-132/-212 in hypertensive rats and humans,” International Journal of Molecular Sciences, vol. 14, no. 6, pp. 11190–11207, 2013. View at Publisher · View at Google Scholar · View at Scopus
  28. T. V. Eskildsen, M. Schneider, M. B. Sandberg et al., “The microRNA-132/212 family fine-tunes multiple targets in Angiotensin II signalling in cardiac fibroblasts,” Journal of the Renin-Angiotensin-Aldosterone System, 2014. View at Publisher · View at Google Scholar
  29. S. Gao, T.-W. Liu, Z. Wang et al., “Downregulation of MicroRNA-19b contributes to angiotensin II-induced overexpression of connective tissue growth factor in cardiomyocytes,” Cardiology, vol. 127, no. 2, pp. 114–120, 2014. View at Publisher · View at Google Scholar · View at Scopus
  30. L.-X. Yang, G. Liu, G.-F. Zhu et al., “MicroRNA-155 inhibits angiotensin II-induced vascular smooth muscle cell proliferation,” Journal of the Renin Angiotensin Aldosterone System, vol. 15, no. 2, pp. 109–116, 2014. View at Publisher · View at Google Scholar
  31. G. Ceolotto, I. Papparella, A. Bortoluzzi et al., “Interplay between miR-155, AT1R A1166C polymorphism, and AT1R expression in young untreated hypertensives,” The American Journal of Hypertension, vol. 24, no. 2, pp. 241–246, 2011. View at Publisher · View at Google Scholar · View at Scopus
  32. D. W. Lambert, L. A. Lambert, N. E. Clarke, N. M. Hooper, K. E. Porter, and A. J. Turner, “Angiotensin-converting enzyme 2 is subject to post-transcriptional regulation by miR-421,” Clinical Science, vol. 127, no. 4, pp. 243–249, 2014. View at Publisher · View at Google Scholar · View at Scopus
  33. Q. Gu, B. Wang, X.-F. Zhang, Y.-P. Ma, J.-D. Liu, and X.-Z. Wang, “Contribution of renin–angiotensin system to exercise-induced attenuation of aortic remodeling and improvement of endothelial function in spontaneously hypertensive rats,” Cardiovascular Pathology, vol. 23, no. 5, pp. 298–305, 2014. View at Publisher · View at Google Scholar
  34. H.-J. Wang, W.-Y. Lo, and L.-J. Lin, “Angiotensin-(1–7) decreases glycated albumin-induced endothelial interleukin-6 expression via modulation of miR-146a,” Biochemical and Biophysical Research Communications, vol. 430, no. 3, pp. 1157–1163, 2013. View at Publisher · View at Google Scholar · View at Scopus
  35. Y. Takahashi, M. Satoh, Y. Minami, T. Tabuchi, T. Itoh, and M. Nakamura, “Expression of miR-146a/b is associated with the Toll-like receptor 4 signal in coronary artery disease: effect of renin-angiotensin system blockade and statins on miRNA-146a/b and Toll-like receptor 4 levels,” Clinical Science, vol. 119, no. 9, pp. 395–405, 2010. View at Publisher · View at Google Scholar · View at Scopus
  36. C. M. Ferrario, J. Jessup, M. C. Chappell et al., “Effect of angiotensin-converting enzyme inhibition and angiotensin II receptor blockers on cardiac angiotensin-converting enzyme 2,” Circulation, vol. 111, no. 20, pp. 2605–2610, 2005. View at Publisher · View at Google Scholar · View at Scopus
  37. J. C. Zhong, J. Y. Ye, H. Y. Jin et al., “Telmisartan attenuates aortic hypertrophy in hypertensive rats by the modulation of ACE2 and profilin-1 expression,” Regulatory Peptides, vol. 166, no. 1-3, pp. 90–97, 2011. View at Publisher · View at Google Scholar · View at Scopus
  38. J. Zhong, R. Basu, D. Guo et al., “Angiotensin-converting enzyme 2 suppresses pathological hypertrophy, myocardial fibrosis, and cardiac dysfunction,” Circulation, vol. 122, no. 7, pp. 717–728, 2010. View at Publisher · View at Google Scholar · View at Scopus
  39. M. Satoh, Y. Takahashi, T. Tabuchi et al., “Circulating Toll-like receptor 4-responsive microRNA panel in patients with coronary artery disease: results from prospective and randomized study of treatment with renin-angiotensin system blockades,” Clinical Science, vol. 128, no. 8, pp. 483–491, 2015. View at Publisher · View at Google Scholar
  40. T. Sato, T. Suzuki, H. Watanabe et al., “Apelin is a positive regulator of ACE2 in failing hearts,” Journal of Clinical Investigation, vol. 123, no. 12, pp. 5203–5211, 2013. View at Publisher · View at Google Scholar · View at Scopus
  41. N. E. Clarke and A. J. Turner, “Angiotensin-converting enzyme 2: the first decade,” International Journal of Hypertension, vol. 2012, Article ID 307315, 12 pages, 2012. View at Publisher · View at Google Scholar · View at Scopus
  42. K. Tatemoto, M. Hosoya, Y. Habata et al., “Isolation and characterization of a novel endogenous peptide ligand for the human APJ receptor,” Biochemical and Biophysical Research Communications, vol. 251, no. 2, pp. 471–476, 1998. View at Publisher · View at Google Scholar · View at Scopus
  43. J. C. Zhong, X. Y. Yu, Y. Huang, L. M. Yung, C. W. Lau, and S. G. Lin, “Apelin modulates aortic vascular tone via endothelial nitric oxide synthase phosphorylation pathway in diabetic mice,” Cardiovascular Research, vol. 74, no. 3, pp. 388–395, 2007. View at Publisher · View at Google Scholar · View at Scopus
  44. M. Przewlocka-Kosmala, T. Kotwica, A. Mysiak, and W. Kosmala, “Reduced circulating apelin in essential hypertension and its association with cardiac dysfunction,” Journal of Hypertension, vol. 29, no. 5, pp. 971–979, 2011. View at Publisher · View at Google Scholar · View at Scopus
  45. H. Najafipour, A. Soltani Hekmat, A. A. Nekooian, and S. Esmaeili-Mahani, “Apelin receptor expression in ischemic and non- ischemic kidneys and cardiovascular responses to apelin in chronic two-kidney-one-clip hypertension in rats,” Regulatory Peptides, vol. 178, no. 1–3, pp. 43–50, 2012. View at Publisher · View at Google Scholar · View at Scopus
  46. R. Akcilar, S. Turgut, V. Caner et al., “Apelin effects on blood pressure and RAS in DOCA-salt-induced hypertensive rats,” Clinical and Experimental Hypertension, vol. 35, no. 7, pp. 550–557, 2013. View at Publisher · View at Google Scholar · View at Scopus
  47. A. F. Ceylan-Isik, M. R. Kandadi, X. Xu et al., “Apelin administration ameliorates high fat diet-induced cardiac hypertrophy and contractile dysfunction,” Journal of Molecular and Cellular Cardiology, vol. 63, pp. 4–13, 2013. View at Publisher · View at Google Scholar · View at Scopus
  48. J. Kim, Y. Kang, Y. Kojima et al., “An endothelial apelin-FGF link mediated by miR-424 and miR-503 is disrupted in pulmonary arterial hypertension,” Nature Medicine, vol. 19, no. 1, pp. 74–82, 2013. View at Publisher · View at Google Scholar · View at Scopus